Published: November 2009
Pharmacogenetics helps us understand the relationship between an individual’s genetic make-up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimise the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits.
The book argues for large-scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using pharmacogenetics to improve the use of existing medicines. Governments and others need to align regulatory, reimbursement and other incentives and work with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training.
This publication is part of the OECD Innovation Strategy, a comprehensive policy strategy to harness innovation for stronger and more sustainable growth and development, and to address the key societal challenges of the 21st century.
Executive Summary (download pdf)
Chapter 1. Introduction to the Policy Issues
Chapter 2. The Supporting Infrastructures for Pharmacogenetics
Chapter 3. Pharmacogenetics and Drug Development
Chapter 4. Business Models for Pharmacogenetics
Chapter 5. Physician and Patient Demand for Pharmacogenetics
Chapter 6. Regulatory Authorities and Reimbursement Mechanisms
Chapter 7. Conclusions
Readers can access the full version of this book choosing from the following options:
Permanent URL of this page: www.oecd.org/sti/biotechnology/pharmacogenetics